Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 500 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus ( Type 1 and Type 2) Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04991532, PF-0499132, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chula Vista, California • Miami, Florida

Conditions: Type I Diabetes
Interventions: OPT101, OPT101 Placebo to Match (PTM); Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Afrezza plus One Drop | Premium, One Drop | Premium; Drug · Other
Lead sponsor: Informed Data Systems, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: DKA
Interventions: Insulin Glargine; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Single Dose PB1023; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05161704 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Retinopathy
Interventions: Placebo, RG7774; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more

Conditions: Healthy
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: Diabetes Assistant (DiAs); Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Santa Barbara, California • Charlottesville, Virginia

Conditions: Diabetes
Interventions: Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring; Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Semaglutide 1 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Pressure Ulcer, Foot Ulcer, Diabetic
Interventions: Santyl, Standard Care; Biological · Other
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: Volinanserin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions; Drug
Lead sponsor: LaTonya J. Hickson; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: t:slim X2 insulin pump with Control-IQ technology 2.0; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Charlottesville, Virginia

Conditions: Diabetes
Interventions: Human Pancreatic Islet Transplantation; Biological
Lead sponsor: Midhat H. Abdulreda; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Weight Loss
Interventions: VK2735; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 135
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes LIVE JustICE, Enhanced Education; Other
Lead sponsor: Louise Reagan; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Storrs, Connecticut • Storrs Mansfield, Connecticut

Conditions: Diabete Mellitus
Interventions: Freestyle Libre; Device
Lead sponsor: Methodist Medical Center of Illinois; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Guardian Sensor (3); Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Type1 Diabetes
Interventions: Glargine; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more

Search by objective public record fields.

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

Dexcom G6 Observational Study

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

Use of Santyl Within an Accountable Care Organization

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus

Stem Cell Therapy for Chronic Kidney Disease

Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

VK2735 for Weight Management Phase 3

Diabetes Learning in Virtual Environments Just in Time for Community Reentry

CGM to Aid Transition From Inpatient to Outpatient

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity